BACKGROUND:Infants with congenital heart disease who require central venous lines are at increased risk of thrombosis. Heparin-bonded catheters provide protection from thrombotic events in some children. However, heparin-bonded catheters may not be as effective in infants </=1 year old because of other potential risk factors (smaller vessel size, longer duration of catheter use). No studies have assessed the benefit of heparin-bonded catheters in such specific high-risk populations. The objective of this study was to assess the efficacy of heparin-bonded catheters for preventing thrombosis in infants aged </=1 year with congenital heart disease. STUDY DESIGN: This study was designed as a randomized, controlled, blinded single-center trial. Infants </=1 year old with congenital heart disease requiring a central venous line for clinical care were randomly assigned to receive either a heparin-bonded catheter or a standard non-heparin-bonded catheter. Catheters were visually indistinguishable. The primary outcome was incidences of both silent and clinically noticeable thrombosis confirmed by ultrasound. Ultrasounds were reviewed by a blinded central adjudication committee. Interim analysis was performed after enrollment of 97 patients. RESULTS:Eighty-seven patients were evaluable (41 of the patients were female). Thrombotic events occurred in 17 (42.5%) of 40 patients in the non-heparin-bonded catheter group and in 21 (44.7%) of 47 patients in the heparin-bonded catheters group. The study was stopped when the interim analysis showed convincing evidence for no difference between groups over the alternative hypothesis of 50% risk reduction. CONCLUSIONS:Infants with congenital heart disease are at significant risk of both silent and clinically identified thrombosis. There seems to be no advantage in using heparin-bonded catheters in infants </=1 year of age.
RCT Entities:
BACKGROUND:Infants with congenital heart disease who require central venous lines are at increased risk of thrombosis. Heparin-bonded catheters provide protection from thrombotic events in some children. However, heparin-bonded catheters may not be as effective in infants </=1 year old because of other potential risk factors (smaller vessel size, longer duration of catheter use). No studies have assessed the benefit of heparin-bonded catheters in such specific high-risk populations. The objective of this study was to assess the efficacy of heparin-bonded catheters for preventing thrombosis in infants aged </=1 year with congenital heart disease. STUDY DESIGN: This study was designed as a randomized, controlled, blinded single-center trial. Infants </=1 year old with congenital heart disease requiring a central venous line for clinical care were randomly assigned to receive either a heparin-bonded catheter or a standard non-heparin-bonded catheter. Catheters were visually indistinguishable. The primary outcome was incidences of both silent and clinically noticeable thrombosis confirmed by ultrasound. Ultrasounds were reviewed by a blinded central adjudication committee. Interim analysis was performed after enrollment of 97 patients. RESULTS: Eighty-seven patients were evaluable (41 of the patients were female). Thrombotic events occurred in 17 (42.5%) of 40 patients in the non-heparin-bonded catheter group and in 21 (44.7%) of 47 patients in the heparin-bonded catheters group. The study was stopped when the interim analysis showed convincing evidence for no difference between groups over the alternative hypothesis of 50% risk reduction. CONCLUSIONS:Infants with congenital heart disease are at significant risk of both silent and clinically identified thrombosis. There seems to be no advantage in using heparin-bonded catheters in infants </=1 year of age.
Authors: N Joram; L de Saint Blanquat; D Stamm; E Launay; C Gras-Le Guen Journal: Eur J Clin Microbiol Infect Dis Date: 2012-04-01 Impact factor: 3.267
Authors: Kamal El Masri; Kimberly Jackson; Santiago Borasino; Mark Law; David Askenazi; Jeffrey Alten Journal: Pediatr Nephrol Date: 2013-09-01 Impact factor: 3.714
Authors: Kagya A Amoako; Christopher Archangeli; Hitesh Handa; Terry Major; Mark E Meyerhoff; Gail M Annich; Robert H Bartlett Journal: ASAIO J Date: 2012 May-Jun Impact factor: 2.872
Authors: Matthew P Lungren; Thomas J Ward; Manish N Patel; John M Racadio; Kamlesh Kukreja Journal: J Thromb Thrombolysis Date: 2015-10 Impact factor: 2.300
Authors: Edward Vincent S Faustino; Sonya Patel; Ravi R Thiagarajan; Deborah J Cook; Veronika Northrup; Adrienne G Randolph Journal: Crit Care Med Date: 2011-07 Impact factor: 7.598
Authors: Jane Yu; Elizabeth Brisbois; Hitesh Handa; Gail Annich; Mark Meyerhoff; Robert Bartlett; Terry Major Journal: J Mater Chem B Date: 2016-03-01 Impact factor: 6.331